EUVIMEDEUVIMED entdecken
Klinische Studie

Feasibility and therapeutic potential of [177Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma

Seyedeh Somayyeh Banihashemian, Mohammad Esmaeil Akbari iD, Elahe Pirayesh, Ghasemali Divband, Abdolghafar Abolhosseini Shahrnoy, Reza Nami, Seyed Mohammad Mazidi, Meysam Nasiri

European Journal of Nuclear Medicine and Molecular Imaging · 2024-12 · 52 (1) · 237-246

DOI: 10.1007/s00259-024-06795-7 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 27.07.2024. Verfasst von Seyedeh Somayyeh Banihashemian und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tajrish Sq, Tehran, 19899-34148, Iran. Hauptthemen laut MEDLINE: Sarcoma, Neoplasm Metastasis, Feasibility Studies. Die Arbeit wurde bisher 75-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: The unique expression pattern of fibroblast activation protein (FAP) in stromal and tumor cells, particularly in sarcomas, and its absence in normal tissues, have positioned it as a promising theragnostic approach for the detection and treatment of various cancer types. The objective of this prospective study is to assess the feasibility, safety, biodistribution, and therapeutic efficacy of [177Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma. PATIENTS AND METHODS: Eight patients with advanced metastatic sarcoma, who were unresectable or had experienced disease recurrence following conventional treatments, underwent PTRT (peptide-targeted radionuclide therapy) using [177Lu]Lu-FAPI-2286. Prior to the treatment, confirmation of tumor uptake was obtained through [68Ga]Ga-FAPI-2286 PET/CT. RESULTS: After four cycles of PTRT with [177Lu]Lu-FAPI-2286 (6660-7400 MBq), with a 6-8-week interval between each cycle, no grade 3 or 4 side effects were observed in the patients, and the treatment was well tolerated by all participants. The results demonstrated a 52.37% reduction in the average volume of the primary tumor, accompanied by a significant decrease in SUVmax and TBR of the metastatic lesions (29.67% and 43.66% respectively), especially in cases of lung metastasis. Furthermore, besides the improvement in physical capacity, there was a noticeable reduction in pain, an increase in overall survival, and enhanced satisfaction with the treatment reported by the patients. CONCLUSION: [177Lu]Lu-FAPI-2286 PTRT, utilized for diverse cancer types, exhibited favorable tolerability in sarcoma patients, with minimal side effects, long-lasting retention of the radiopeptide within the tumor, and promising therapeutic effects. Preliminary findings of this prospective study need to be confirmed through further clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcomaNeoplasm MetastasisFeasibility StudiesHumansMaleFemaleMiddle AgedAdultLutetiumAgedTissue DistributionTreatment OutcomeRadioisotopesRadiopharmaceuticalsPositron Emission Tomography Computed Tomography

Stichwörter der Autor:innen

177 lutetiumFAP-2286Fibroblast activation protein (FAP)Radionuclide therapySarcoma

Substanzen

LutetiumLutetium-177RadioisotopesRadiopharmaceuticals

Autor:innen und Institutionen

  • Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tajrish Sq, Tehran, 19899-34148, Iran.
  • Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tajrish Sq, Tehran, 19899-34148, Iran. profmeakbari@gmail.com.
  • Department of Nuclear Medicine, Shohada'e Tajrish Medical Center, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Khatam PET-CT Center, Khatam Hospital, Tehran, Iran.
  • Parsisotope Company, Tehran, Iran.
  • Department of Cellular and Molecular Biology, School of Biology, Damghan University, Damghan, Iran.

ORCID-Profile: Mohammad Esmaeil Akbari

Zitieren

APA

Banihashemian, S. S., Akbari, M. E., Pirayesh, E., Divband, G., Abolhosseini Shahrnoy, A., Nami, R., Mazidi, S. M., & Nasiri, M. (2024). Feasibility and therapeutic potential of [177Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma. European Journal of Nuclear Medicine and Molecular Imaging, 52(1), 237-246. https://doi.org/10.1007/s00259-024-06795-7

Vancouver

Banihashemian SS, Akbari ME, Pirayesh E, Divband G, Abolhosseini Shahrnoy A, Nami R, et al. Feasibility and therapeutic potential of [177Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma. European Journal of Nuclear Medicine and Molecular Imaging. 2024;52(1):237-246. doi:10.1007/s00259-024-06795-7

BibTeX
@article{Banihashemian2024,
  author = {Banihashemian, Seyedeh Somayyeh and Akbari, Mohammad Esmaeil and Pirayesh, Elahe and Divband, Ghasemali and Abolhosseini Shahrnoy, Abdolghafar and Nami, Reza and Mazidi, Seyed Mohammad and Nasiri, Meysam},
  title = {Feasibility and therapeutic potential of [177Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2024},
  volume = {52},
  number = {1},
  pages = {237--246},
  doi = {10.1007/s00259-024-06795-7}
}
Kostenlos starten →